RxDoctor Payments DataLook up a doctor →

James Herrmann, MD

Dermatology · Wheaton, ILNPI 1407822216

Payments from drug & device makers

$583,343in general payments, 2019–2025

Across 494 payments — averaging $1180.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$268K
  • Eli Lilly$139K
  • Janssen Scientific Affairs, LLC$56K
  • Novartis$28K
  • Johnson & Johnson$22K
  • Regeneron Healthcare Solutions, Inc.$20K
  • plus $51K from 15 others
$9,450in research payments, 2019–2025

Across 1 payment — averaging $9450.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$9K

What the payments were for

  • Consulting fees$4,9252%
  • Speaking & faculty fees$302,45694%
  • Travel & lodging$2,7491%
  • Food & beverage$9,9853%
  • Education$2830%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$583,343 in reported general payments places this provider in the 95th percentile of 606 dermatology providers in Illinois.

See all dermatology providers in Illinois

Medicare billing

Part B allowed, 2024
$254,527
Medicare patients
640
Services billed
3,319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Unoready PenSecukinumab14$131,973
RinvoqUpadacitinib12$86,422
Fluorouracil37$2,209
Mycophenolate Mofetil12$1,740
Doxycycline Monohydrate17$926
Hydrocortisone Butyrate11$805
Triamcinolone Acetonide70$736
Fluocinonide16$660
ValacyclovirValacyclovir Hcl11$527
Metronidazole11$457
Clobetasol Propionate20$417
Doxycycline Hyclate14$381
Hydrocortisone17$350
Ketoconazole25$312
Alclometasone Dipropionate13$293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$267,846$86,42212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 606 dermatology providers in Illinois.

Other dermatology in Wheaton

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →